Global Pharmaceutical Cartridges Market - Forecasts from 2020 to 2025
The global pharmaceutical cartridges market is projected to grow at a CAGR of 4.02% to reach a market size of US$1.543 billion in 2025. As a result of the growing demand for effective packaging solutions for preventing drug contamination, the pharmaceutical packaging cartridges market hold strong growth prospects in the forecast period. Thus, the growing pharmaceutical packaging industry is fueling the market demand. The growing chronic disease prevalence is driving market growth in the forecast period. With growing diabetes globally, the insulin delivery systems using pre-fillable syringes is further augmenting the market demand. The growing geriatric population accompanied by the age-associated diseases are further propelling the market demand in the forecast period. Also, cartridges form an important part of many drug delivery systems, hence, with the growing drug delivery industry, the market is poised to grow at a significant pace. The growing biomedical and biotech research worldwide, the use of cartridges is immense in the biotech companies and in the biomedical research organizations apart from the pharmaceutical organizations. Hence, these are further providing an opportunity for the market to thrive in the forecast period and in the upcoming years.
Geographically, the USA from the North American region is estimated to hold a significant market share with high expenditure and a well-established pharmaceutical industry here. On the other hand, Asia Pacific is projected to grow with a high CAGR especially in the developing economies of India and China owing to the high prevalence of people suffering from chronic diseases like diabetes and are insulin-dependent.
The prevalence of insulin-dependent diabetes, type 1 and type 2 is augmenting the market demand in the forecast period.
According to the American Diabetes Association, ADA, the prevalence of individuals with type 1 diabetes where pancreas is not capable of producing insulin is prevalent. More than one million Americans have this disease. Type 2 diabetes is the most common form of diabetes found in the United States, according to CDC, more than 90% of individuals are diagnosed with this disease. However, not everyone is recommended for insulin injections. In 2018, 34.2 million Americans were affected with diabetes and around 1.6 million Americans were found to have type 1 diabetes which included nearly 187,000 children and adolescents (source: ADA).
Hence, with the high disease prevalence, the market for insulin cartridges holds strong growth prospects in the United States and in the other parts of the world.
According to the WHO, in 2016, diabetes was the reason for the 1.6 million deaths globally. Furthermore, the common consequences of diabetes include damage to heart, blood vessels, kidney, eyes, and nerves. Individuals suffering from diabetes are at an increased risk of heart attacks and strokes. With reduced blood flow there are high chances of nerve damage in the feet which raises the chances of foot ulcers, infection resulting in limb amputation. Also, diabetic retinopathy plays an important role in causing blindness due to damage to small blood vessels in the retina. It is estimated that this contributes to around 2% of the blindness at the global level. Hence, effective measures are taken for early disease diagnosis and prevention, also, in the case of severe diabetes requiring insulin drug delivery, the market is propelled to grow at a significant pace in the forecast period.
As per the International Diabetes Federation (IDF) Statistics, at present after every 7 seconds, a person is estimated to die with diabetes or diabetes related complications, accounting to around 4 million deaths every year. Around 50% of the total deaths is accounted to occur under the age of 60 years.
The prevalence is estimated to increase to 9.9% by 2045 from a predicted prevalence of 8.8% of the total global population in 2017. In 2017, 424.9 million were affected by diabetes globally, and this is projected to surge to 628.6 million individuals by the end of 2045.
The presence of companies offering varied products of different capacities as per the customers’ demand is surging the market growth in the forecast period.
Various drug delivery devices that make use of multi-use pens or pen injectors demand cartridge technology for safe drug storage and also hold suitability for high-viscosity drugs under various storage conditions.
West Pharmaceutical Services Daikyo Crystal Zenith® cartridges provide superior predictable functionality, safety, and compatibility with varied devices. This comprises of crystal zenith polymer. These cartridges offer superior barrier protection, superior functional performance without silicone oil, compatibility for high-viscosity drugs, tight dimensional tolerances, and suitability for auto-injectors and pen-delivery systems.
The company’s SmartDose® Generation I drug delivery platform approved by the US FDA offers a wearable subcutaneous injector with an integrated drug delivery system for delivering a truly patient-centric approach to self-administration. The device is capable of user loaded, subcutaneous self-administration, is capable of introducing high volume and high viscosity drug products, connectivity capable, and easy and convenient in operation
SCHOTT AG offers a broad range of containers, quality levels, and controlled surface chemistry for the fulfillment of the customized needs of primary packaging. The cartridges are manufactured and packed in an environmentally controlled area with ISO 9001 and ISO 15378 certification. Also, these comply with PH. Eur., USP, and JP international standards. Schott cartridges are manufactured on the basis of advanced production lines containing highly stable and validated processes. The permanent process optimization is achieved through Six Sigma principles, in addition to the professional training provided to the employees which contributes to maintaining the quality to the highest levels. The cartridge handling is continuously optimized in decreasing glass-to-glass contact, hence, leading to an increase in mechanical strength and exceptional cosmetic quality.
Gerresheimer cartridges are high-quality cartridges with fill volumes that range from 1.5 ml to 3.0 ml. Also, up to 10 ml can be manufactured as per the customer’s need for various pharma applications. The product range consists of clear and amber cartridges that are made of borosilicate glass of hydrolytic class I. There are options for ammonium sulphate treatment for an enhanced surface resistance. The company manufactures cartridges of dental applications and cartridges for pen drug delivery systems.
Segmentation:
Geographically, the USA from the North American region is estimated to hold a significant market share with high expenditure and a well-established pharmaceutical industry here. On the other hand, Asia Pacific is projected to grow with a high CAGR especially in the developing economies of India and China owing to the high prevalence of people suffering from chronic diseases like diabetes and are insulin-dependent.
The prevalence of insulin-dependent diabetes, type 1 and type 2 is augmenting the market demand in the forecast period.
According to the American Diabetes Association, ADA, the prevalence of individuals with type 1 diabetes where pancreas is not capable of producing insulin is prevalent. More than one million Americans have this disease. Type 2 diabetes is the most common form of diabetes found in the United States, according to CDC, more than 90% of individuals are diagnosed with this disease. However, not everyone is recommended for insulin injections. In 2018, 34.2 million Americans were affected with diabetes and around 1.6 million Americans were found to have type 1 diabetes which included nearly 187,000 children and adolescents (source: ADA).
Hence, with the high disease prevalence, the market for insulin cartridges holds strong growth prospects in the United States and in the other parts of the world.
According to the WHO, in 2016, diabetes was the reason for the 1.6 million deaths globally. Furthermore, the common consequences of diabetes include damage to heart, blood vessels, kidney, eyes, and nerves. Individuals suffering from diabetes are at an increased risk of heart attacks and strokes. With reduced blood flow there are high chances of nerve damage in the feet which raises the chances of foot ulcers, infection resulting in limb amputation. Also, diabetic retinopathy plays an important role in causing blindness due to damage to small blood vessels in the retina. It is estimated that this contributes to around 2% of the blindness at the global level. Hence, effective measures are taken for early disease diagnosis and prevention, also, in the case of severe diabetes requiring insulin drug delivery, the market is propelled to grow at a significant pace in the forecast period.
As per the International Diabetes Federation (IDF) Statistics, at present after every 7 seconds, a person is estimated to die with diabetes or diabetes related complications, accounting to around 4 million deaths every year. Around 50% of the total deaths is accounted to occur under the age of 60 years.
The prevalence is estimated to increase to 9.9% by 2045 from a predicted prevalence of 8.8% of the total global population in 2017. In 2017, 424.9 million were affected by diabetes globally, and this is projected to surge to 628.6 million individuals by the end of 2045.
The presence of companies offering varied products of different capacities as per the customers’ demand is surging the market growth in the forecast period.
Various drug delivery devices that make use of multi-use pens or pen injectors demand cartridge technology for safe drug storage and also hold suitability for high-viscosity drugs under various storage conditions.
West Pharmaceutical Services Daikyo Crystal Zenith® cartridges provide superior predictable functionality, safety, and compatibility with varied devices. This comprises of crystal zenith polymer. These cartridges offer superior barrier protection, superior functional performance without silicone oil, compatibility for high-viscosity drugs, tight dimensional tolerances, and suitability for auto-injectors and pen-delivery systems.
The company’s SmartDose® Generation I drug delivery platform approved by the US FDA offers a wearable subcutaneous injector with an integrated drug delivery system for delivering a truly patient-centric approach to self-administration. The device is capable of user loaded, subcutaneous self-administration, is capable of introducing high volume and high viscosity drug products, connectivity capable, and easy and convenient in operation
SCHOTT AG offers a broad range of containers, quality levels, and controlled surface chemistry for the fulfillment of the customized needs of primary packaging. The cartridges are manufactured and packed in an environmentally controlled area with ISO 9001 and ISO 15378 certification. Also, these comply with PH. Eur., USP, and JP international standards. Schott cartridges are manufactured on the basis of advanced production lines containing highly stable and validated processes. The permanent process optimization is achieved through Six Sigma principles, in addition to the professional training provided to the employees which contributes to maintaining the quality to the highest levels. The cartridge handling is continuously optimized in decreasing glass-to-glass contact, hence, leading to an increase in mechanical strength and exceptional cosmetic quality.
Gerresheimer cartridges are high-quality cartridges with fill volumes that range from 1.5 ml to 3.0 ml. Also, up to 10 ml can be manufactured as per the customer’s need for various pharma applications. The product range consists of clear and amber cartridges that are made of borosilicate glass of hydrolytic class I. There are options for ammonium sulphate treatment for an enhanced surface resistance. The company manufactures cartridges of dental applications and cartridges for pen drug delivery systems.
Segmentation:
- By Material
- Glass
- Plastic
- By Cartridge Size
- Less than 3ml
- 3ml to 5ml
- 5ml to 10ml
- Greater than 10ml
- By End User
- Pharmaceutical Company
- Biotech Company
- Biomedical Research Organization
- By Geography
- North America
- USA
- Canada
- Mexico
- South America
- Brazil
- Argentina
- Others
- Europe
- UK
- Germany
- France
- Others
- Middle East and Africa
- UAE
- Israel
- Saudi Arabia
- Others
- Asia Pacific
- Japan
- China
- India
- Australia
- Others
1. INTRODUCTION
1.1. Market Definition
1.2. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Market Opportunities
4.4. Porters Five Forces Analysis
4.4.1. Bargaining Power of Suppliers
4.4.2. Bargaining Power of Buyers
4.4.3. Threat of New Entrants
4.4.4. Threat of Substitutes
4.4.5. Competitive Rivalry in the Industry
4.5. Industry Value Chain Analysis
5. GLOBAL PHARMACEUTICAL CARTRIDGES MARKET ANALYSIS, BY MATERIAL
5.1. Introduction
5.2. Glass
5.3. Plastic
6. GLOBAL PHARMACEUTICAL CARTRIDGES MARKET ANALYSIS, BY CARTRIDGE SIZE
6.1. Introduction
6.2. Less than 3ml
6.3. 3ml to 5ml
6.4. 5ml to 10ml
6.5. Greater than 10ml
7. GLOBAL PHARMACEUTICAL CARTRIDGES MARKET ANALYSIS, BY END USER
7.1. Introduction
7.2. Pharmaceutical Company
7.3. Biotech Company
7.4. Biomedical Research Organization
8. GLOBAL PHARMACEUTICAL CARTRIDGES MARKET ANALYSIS, BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. North America Pharmaceutical Cartridges Market, By Material
8.2.2. North America Pharmaceutical Cartridges Market, By Cartridge Size
8.2.3. North America Pharmaceutical Cartridges Market, By End User
8.2.4. By Country
8.2.4.1. United States
8.2.4.2. Canada
8.2.4.3. Mexico
8.3. South America
8.3.1. South America Pharmaceutical Cartridges Market, By Material
8.3.2. South America Pharmaceutical Cartridges Market, By Cartridge Size
8.3.3. South America Pharmaceutical Cartridges Market, By End User
8.3.4. By Country
8.3.4.1. Brazil
8.3.4.2. Argentina
8.3.4.3. Others
8.4. Europe
8.4.1. Europe Pharmaceutical Cartridges Market, By Material
8.4.2. Europe Pharmaceutical Cartridges Market, By Cartridge Size
8.4.3. Europe Pharmaceutical Cartridges Market, By End User
8.4.4. By Country
8.4.4.1. UK
8.4.4.2. Germany
8.4.4.3. France
8.4.4.4. Others
8.5. Middle East and Africa
8.5.1. Middle East and Africa Pharmaceutical Cartridges Market, By Material
8.5.2. Middle East and Africa Pharmaceutical Cartridges Market, By Cartridge Size
8.5.3. Middle East and Africa Pharmaceutical Cartridges Market, By End User
8.5.4. By Country
8.5.4.1. United Arab Emirates
8.5.4.2. Israel
8.5.4.3. Saudi Arabia
8.5.4.4. Others
8.6. Asia Pacific
8.6.1. Asia Pacific Pharmaceutical Cartridges Market, By Material
8.6.2. Asia Pacific Pharmaceutical Cartridges Market, By Cartridge Size
8.6.3. Asia Pacific Pharmaceutical Cartridges Market, By End User
8.6.4. By Country
8.6.4.1. Japan
8.6.4.2. China
8.6.4.3. India
8.6.4.4. Australia
8.6.4.5. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Emerging Players and Market Lucrativeness
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Vendor Competitiveness Matrix
10. COMPANY PROFILES
10.1. Gerresheimer AG
10.2. Stevanato Group
10.3. SCHOTT AG
10.4. West Pharmaceutical Services, Inc.
10.5. Transcoject GmbH
10.6. Sigma-Aldrich, Inc.
10.7. Pierrel S.p.A.
10.8. Nipro Corporation
1.1. Market Definition
1.2. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Market Opportunities
4.4. Porters Five Forces Analysis
4.4.1. Bargaining Power of Suppliers
4.4.2. Bargaining Power of Buyers
4.4.3. Threat of New Entrants
4.4.4. Threat of Substitutes
4.4.5. Competitive Rivalry in the Industry
4.5. Industry Value Chain Analysis
5. GLOBAL PHARMACEUTICAL CARTRIDGES MARKET ANALYSIS, BY MATERIAL
5.1. Introduction
5.2. Glass
5.3. Plastic
6. GLOBAL PHARMACEUTICAL CARTRIDGES MARKET ANALYSIS, BY CARTRIDGE SIZE
6.1. Introduction
6.2. Less than 3ml
6.3. 3ml to 5ml
6.4. 5ml to 10ml
6.5. Greater than 10ml
7. GLOBAL PHARMACEUTICAL CARTRIDGES MARKET ANALYSIS, BY END USER
7.1. Introduction
7.2. Pharmaceutical Company
7.3. Biotech Company
7.4. Biomedical Research Organization
8. GLOBAL PHARMACEUTICAL CARTRIDGES MARKET ANALYSIS, BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. North America Pharmaceutical Cartridges Market, By Material
8.2.2. North America Pharmaceutical Cartridges Market, By Cartridge Size
8.2.3. North America Pharmaceutical Cartridges Market, By End User
8.2.4. By Country
8.2.4.1. United States
8.2.4.2. Canada
8.2.4.3. Mexico
8.3. South America
8.3.1. South America Pharmaceutical Cartridges Market, By Material
8.3.2. South America Pharmaceutical Cartridges Market, By Cartridge Size
8.3.3. South America Pharmaceutical Cartridges Market, By End User
8.3.4. By Country
8.3.4.1. Brazil
8.3.4.2. Argentina
8.3.4.3. Others
8.4. Europe
8.4.1. Europe Pharmaceutical Cartridges Market, By Material
8.4.2. Europe Pharmaceutical Cartridges Market, By Cartridge Size
8.4.3. Europe Pharmaceutical Cartridges Market, By End User
8.4.4. By Country
8.4.4.1. UK
8.4.4.2. Germany
8.4.4.3. France
8.4.4.4. Others
8.5. Middle East and Africa
8.5.1. Middle East and Africa Pharmaceutical Cartridges Market, By Material
8.5.2. Middle East and Africa Pharmaceutical Cartridges Market, By Cartridge Size
8.5.3. Middle East and Africa Pharmaceutical Cartridges Market, By End User
8.5.4. By Country
8.5.4.1. United Arab Emirates
8.5.4.2. Israel
8.5.4.3. Saudi Arabia
8.5.4.4. Others
8.6. Asia Pacific
8.6.1. Asia Pacific Pharmaceutical Cartridges Market, By Material
8.6.2. Asia Pacific Pharmaceutical Cartridges Market, By Cartridge Size
8.6.3. Asia Pacific Pharmaceutical Cartridges Market, By End User
8.6.4. By Country
8.6.4.1. Japan
8.6.4.2. China
8.6.4.3. India
8.6.4.4. Australia
8.6.4.5. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Emerging Players and Market Lucrativeness
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Vendor Competitiveness Matrix
10. COMPANY PROFILES
10.1. Gerresheimer AG
10.2. Stevanato Group
10.3. SCHOTT AG
10.4. West Pharmaceutical Services, Inc.
10.5. Transcoject GmbH
10.6. Sigma-Aldrich, Inc.
10.7. Pierrel S.p.A.
10.8. Nipro Corporation
